Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

39.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The predictive value of lesion density in enhancing multiparametric MRI for detecting clinically significant prostate cancer.

Urologic oncology·2026
Same author

Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development.

Holistic integrative oncology·2025
Same author

Comparative analysis of apixaban vs. enoxaparin for thromboprophylaxis after radical cystectomy A single-center, observational, before-after study.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.

Cell genomics·2025
Same author

Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Apr 14, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Takashi Matsuoka1,2,3,4, Shusuke Akamatsu5, Christopher J Ong1,3

  • 1Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.

Cells
|April 13, 2026
PubMed
Summary
This summary is machine-generated.

Poly(ADP-ribose) polymerase inhibitors (PARPi) offer new hope for advanced prostate cancer, particularly BRCA2-altered tumors. Understanding DNA damage response rewiring is key to overcoming resistance and improving long-term outcomes.

Keywords:
BRCA1/2PARP inhibitorsandrogen deprivation therapy (ADT)androgen receptor pathway inhibitors (ARPI)biomarkerscombination therapyhomologous recombination repair (HRR)metastatic castration-resistant prostate cancer (mCRPC)metastatic castration-sensitive prostate cancer (mCSPC)

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.2K

Related Experiment Videos

Last Updated: Apr 14, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.2K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly(ADP-ribose) polymerase inhibitors (PARPi) have transformed advanced prostate cancer treatment.
  • Durable responses are mainly seen in BRCA1/2-altered tumors, but resistance eventually develops.
  • A unifying model is needed to explain PARPi response and resistance mechanisms.

Purpose of the Study:

  • To present a unifying model of PARPi response and resistance in prostate cancer.
  • To synthesize clinical and translational evidence for PARPi monotherapy and combinations.
  • To outline strategies for biomarker-informed treatment and resistance interception.

Main Methods:

  • Review of clinical and translational evidence for PARPi therapy.
  • Analysis of PARPi response in different prostate cancer settings (mCRPC, mCSPC).
  • Synthesis of data on combination strategies and biomarker utility.

Main Results:

  • PARPi plus androgen receptor pathway inhibition (ARPI) improves outcomes in first-line mCRPC, especially in HRR-altered tumors.
  • PARPi monotherapy shows activity in BRCA2-mutated disease, but responses are variable for other HRR alterations.
  • Treatment-induced dormancy and therapy-tolerant residual states contribute to minimal residual disease (MRD).

Conclusions:

  • DDR rewiring, dormancy, and residual states are central to PARPi response and resistance.
  • Biomarkers beyond gene panels are needed for patient selection in later-line settings.
  • Combination strategies and proactive management of MRD and resistance are crucial for durable benefit.